Journal of Global Infectious DiseasesOfficial Publishing of INDUSEM and OPUS 12 Foundation, Inc. Users online:618  
Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size     
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 
 

    Article Cited by others

SYMPOSIUM - LIESHMANIASIS

Leishmaniasis vaccine: Where are we today?

Kedzierski Lukasz

Year : 2010| Volume: 2| Issue : 2 | Page no: 177-185

   This article has been cited by
 
1 Proteome Profiling of Human Cutaneous Leishmaniasis Lesion
Claire da Silva Santos,Sanaz Attarha,Ravi Kanth Saini,Viviane Boaventura,Jackson Costa,Ricardo Khouri,Manoel Barral-Netto,Cláudia Ida Brodskyn,Serhiy Souchelnytskyi
Journal of Investigative Dermatology. 2014;
[Pubmed]  [Google Scholar] [DOI]
2 A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis – an experimental study
Jyoti Joshi,Nancy Malla,Sukhbir Kaur
Parasitology International. 2014;
[Pubmed]  [Google Scholar] [DOI]
3 Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains
Dirlei Nico,Daniele Crespo Gomes,Marcus Vinícius Alves-Silva,Elisangela Oliveira Freitas,Alexandre Morrot,Diana Bahia,Marcos Palatnik,Mauricio M. Rodrigues,Clarisa B. Palatnik-de-Sousa
Frontiers in Immunology. 2014; 5
[Pubmed]  [Google Scholar] [DOI]
4 Identifying vaccine targets for anti-leishmanial vaccine development
Shyam Sundar,Bhawana Singh
Expert Review of Vaccines. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]
5 FOXP3 expression and frequency of regulatory T cells in healed individuals from Leishmania major infection and the asymptomatic cases
Fariborz Bahrami,Haiedeh Darabi,Farhad Riazi-Rad,Vahid Khaze,Soheila Ajdary,Mohammad Hossein Alimohammadian
Human Immunology. 2014;
[Pubmed]  [Google Scholar] [DOI]
6 Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches
Sumit Joshi,Keerti Rawat,Narendra Kumar Yadav,Vikash Kumar,Mohammad Imran Siddiqi,Anuradha Dube
Frontiers in Immunology. 2014; 5
[Pubmed]  [Google Scholar] [DOI]
7 Immune signal transduction in leishmaniasis from natural to artificial systems: Role of feedback loop insertion
Milsee Mol,Milind S. Patole,Shailza Singh
Biochimica et Biophysica Acta (BBA) - General Subjects. 2014; 1840(1): 71
[Pubmed]  [Google Scholar] [DOI]
8 Exploring the Role of Medicinal Plant-Based Immunomodulators for Effective Therapy of Leishmaniasis
Garima Chouhan,Mohammad Islamuddin,Dinkar Sahal,Farhat Afrin
Frontiers in Immunology. 2014; 5
[Pubmed]  [Google Scholar] [DOI]
9 Chronic infection by Leishmania amazonensis mediated through MAPK ERK mechanisms
Pedro A. Martinez,Christine A. Petersen
Immunologic Research. 2014;
[Pubmed]  [Google Scholar] [DOI]
10 Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis
Bhavana Sethu Lakshmi,Ruobing Wang,Rentala Madhubala
Vaccine. 2014;
[Pubmed]  [Google Scholar] [DOI]
11 Macrophage Cytokines: Involvement in Immunity and Infectious Diseases
Guillermo Arango Duque,Albert Descoteaux
Frontiers in Immunology. 2014; 5
[Pubmed]  [Google Scholar] [DOI]
12 Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins
Maria Agallou,Evita Athanasiou,Olga Koutsoni,Eleni Dotsika,Evdokia Karagouni
Frontiers in Immunology. 2014; 5
[Pubmed]  [Google Scholar] [DOI]
13 Leishmania spp. Proteome Data Sets: A Comprehensive Resource for Vaccine Development to Target Visceral Leishmaniasis
Toni Aebischer
Frontiers in Immunology. 2014; 5
[Pubmed]  [Google Scholar] [DOI]
14 Isobenzofuranone derivatives exhibit antileishmanial effect by inhibiting type II DNA topoisomerase and inducing host response
Amartya Mishra,Jayaraman Vinayagam,Sourav Saha,Sayan Chowdhury,Somenath Roychowdhury,Parasuraman Jaisankar,Hemanta K. Majumder
Pharmacology Research & Perspectives. 2014; 2(6): n/a
[Pubmed]  [Google Scholar] [DOI]
15 Cheminformatic models based on machine learning for pyruvate kinase inhibitors of Leishmania mexicana
Salma Jamal,Vinod Scaria
BMC Bioinformatics. 2013; 14(1): 329
[Pubmed]  [Google Scholar] [DOI]
16 Interactions of antiparasitic alkaloids withLeishmaniaprotein targets: a molecular docking analysis
Ifedayo Victor Ogungbe,Joseph D Ng,William N Setzer
Future Medicinal Chemistry. 2013; 5(15): 1777
[Pubmed]  [Google Scholar] [DOI]
17 Investigation of antileishmanial activities of Tio2@Ag nanoparticles on biological properties of L. tropica and L. infantum parasites, in vitro
Adil M. Allahverdiyev,Emrah Sefik Abamor,Melahat Bagirova,Serap Yesilkir Baydar,Sezen Canim Ates,Figen Kaya,Cengiz Kaya,Miriam Rafailovich
Experimental Parasitology. 2013; 135(1): 55
[Pubmed]  [Google Scholar] [DOI]
18 Vaccination model for visceral leishmaniasis with infective immigrants
Ibrahim M. ELmojtaba,J.Y.T. Mugisha,Mohsin H.A. Hashim
Mathematical Methods in the Applied Sciences. 2013; 36(2): 216
[Pubmed]  [Google Scholar] [DOI]
19 Micro/nanoparticle adjuvants for antileishmanial vaccines: Present and future trends
Ali Badiee,Vahid Heravi Shargh,Ali Khamesipour,Mahmoud Reza Jaafari
Vaccine. 2013; 31(5): 735
[Pubmed]  [Google Scholar] [DOI]
20 TLR-mediated distinct IFN-?/IL-10 pattern induces protective immunity against murine visceral leishmaniasis
Joydeep Paul,Subir Karmakar,Tripti De
European Journal of Immunology. 2012; 42(8): 2087
[Pubmed]  [Google Scholar] [DOI]
21 Leishmaniasis cutánea
Julián Díaz Sánchez,Sagrario Barrientos Serrano,Silvia Morell Mañas
FMC - Formación Médica Continuada en Atención Primaria. 2012; 19(3): 117
[Pubmed]  [Google Scholar] [DOI]
22 Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection
Felix Hugentobler,Raphaël B. Di Roberto,Joshua Gillard,Benoit Cousineau
Vaccine. 2012; 30(39): 5726
[Pubmed]  [Google Scholar] [DOI]
23 Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection
S.A. Campbell,J. Alawa,B. Doro,F.L. Henriquez,C.W. Roberts,A. Nok,C.B.I. Alawa,M. Alsaadi,A.B. Mullen,K.C. Carter
Vaccine. 2012; 30(7): 1357
[Pubmed]  [Google Scholar] [DOI]
24 Characterization of Leishmania infantum thiol-dependent reductase 1 and evaluation of its potential to induce immune protection
A. M. SILVA,J. TAVARES,R. SILVESTRE,A. OUAISSI,G. H. COOMBS,A. CORDEIRO-da-SILVA
Parasite Immunology. 2012; 34(6): 345
[Pubmed]  [Google Scholar] [DOI]
25 Proteoliposomes in nanobiotechnology
P. Ciancaglini,A. M. S. Simão,M. Bolean,J. L. Millán,C. F. Rigos,J. S. Yoneda,M. C. Colhone,R. G. Stabeli
Biophysical Reviews. 2012; 4(1): 67
[Pubmed]  [Google Scholar] [DOI]
26 Innate Immunity and Leishmania Vaccination Strategies
Ron Birnbaum,Noah Craft
Dermatologic Clinics. 2011; 29(1): 89
[Pubmed]  [Google Scholar] [DOI]
27 Visceral leishmaniasis: immunology and prospects for a vaccine
P. M. Kaye,T. Aebischer
Clinical Microbiology and Infection. 2011; 17(10): 1462
[Pubmed]  [Google Scholar] [DOI]
28 Preparation of highly infective Leishmania promastigotes by cultivation on SNB-9 biphasic medium
Igor Grekov,Milena Svobodová,Eva Nohýnková,Marie Lipoldová
Journal of Microbiological Methods. 2011; 87(3): 273
[Pubmed]  [Google Scholar] [DOI]
29 Actualités sur les leishmanioses viscérales
B. Faucher,R. Piarroux
La Revue de Médecine Interne. 2011; 32(9): 544
[Pubmed]  [Google Scholar] [DOI]
30 Leishmaniasis: complexity at the host–pathogen interface
Paul Kaye,Phillip Scott
Nature Reviews Microbiology. 2011; 9(8): 604
[Pubmed]  [Google Scholar] [DOI]

 

Read this article
Sitemap | What's New | Feedback | Copyright and Disclaimer | Contact Us
© 2008 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow
Online since 10th December, 2008